HKEX Launches Hang Seng Biotech Index Futures

2025-12-15 · Indices · QuoteReporter

# HKEX Launches Hang Seng Biotech Index Futures: A Major Boost to the Product Ecosystem

On **November 28, 2025**, Hong Kong Exchanges and Clearing Limited (HKEX) officially launched futures contracts on the **Hang Seng Biotech Index (HSBIO)**. This marks a pivotal milestone for the index—launched nearly six years ago—completing a robust product ecosystem that now includes exchange-traded products (ETPs), index funds, and derivatives.

The HSBIO has delivered an impressive **+80.4%** year-to-date return (as of December 5, 2025), significantly outperforming the Hang Seng Composite Index (HSCI) at **+33.8%**.

## Early Trading Volume and Historical Comparisons

In the first six trading days (November 28 to December 5, 2025), average daily volume stood at approximately **130 contracts**.

For context:

Index Futures	First-Year Avg Daily Volume	Subsequent Growth
Hang Seng TECH (HSTECH, launched 2020)	~1,800 contracts	CAGR 274% (2020–2025)
Hang Seng China Enterprises (HSCEI, launched 2003)	~3,200 contracts	CAGR 213% (2003–2008)

As ecosystems mature, trading activity typically accelerates significantly.

## Contract Specifications

Feature	HSBIO Futures	HSI Futures	HSCEI Futures	HSTECH Futures
Underlying Index	HSBIO	HSI	HSCEI	HSTECH
Contract Multiplier	HK$50 per point	HK$50 per point	HK$50 per point	HK$50 per point
Minimum Fluctuation	1 index point	1 index point	1 index point	1 index point
Trading Hours	9:15am–12:00pm, 1:00pm–4:30pm, 5:15pm–3:00am	Same	Same	Same
Exchange Fee	HK$5	HK$10	HK$3.50	HK$5

## About the Hang Seng Biotech Index (HSBIO)

Launched in December 2019, HSBIO tracks **30** Southbound-eligible biotech companies listed in Hong Kong (including Chapter 18A listings).

Subsector breakdown (as of December 5, 2025):
– Biotechnology: **50%**
– Pharmaceuticals: **40%**

### Top 10 Constituents

Rank	Code	Company	Subsector	Weighting
1	6160.HK	BEIGENE MEDICINES	Biotechnology	11.1%
2	2269.HK	WUXI BIO	Biotechnology	10.3%
3	1801.HK	INNOVENT BIO	Biotechnology	9.9%
4	9926.HK	AKESO	Biotechnology	8.0%
5	1177.HK	SINO BIOPHARM	Pharmaceuticals	6.8%
Top 10 Subtotal				70.0%

## Strong Performance Drivers

Over the past 12 months, HSBIO rose **+76.8%**, outperforming HSCI by 40 percentage points. This rebound—after four consecutive declining years—stems from supportive Mainland policies and the global expansion of Chinese biotech firms.

Notably, out-licensing deals by Chinese pharma companies surged from under $100M in 2019 to **$52B in 2024** (CAGR **249%**).

## Outlook: Options Likely Next

Historically, HKEX has followed index futures launches with options contracts within months (e.g., HSCEI futures in 2003 → options in 2004; HSTECH futures in 2020 → options in 2021). Market participants can anticipate similar developments for HSBIO.

This launch solidifies Hong Kong’s position as a premier hub for biotech investment products, offering investors new tools to gain exposure to one of Asia’s fastest-growing sectors.

Disclaimer
The content on MarketsFN.com is provided for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or trading guidance. All investments involve risks, and past performance does not guarantee future results. You are solely responsible for your investment decisions and should conduct independent research and consult a qualified financial advisor before acting. MarketsFN.com and its authors are not liable for any losses or damages arising from your use of this information.